BNP Paribas Exane Sees Big Upside for Astera Labs
BNP Paribas Exane initiates coverage on Astera Labs with an Outperform rating and $225 target, citing strong long-term opportunities despite recent stock weakness.
NOTRELOAD AI
GE Vernova Stock Surges on Taiwan Wind Power Deal
GE Vernova shares jump after landing first international wind turbine upgrade contract with Taiwan Power Company, marking major expansion milestone.
FDA Approves Eylea HD for Retinal Vein Occlusion Treatment
Regeneron's Eylea HD receives FDA approval for treating macular edema from retinal vein occlusion with flexible dosing options, potentially reducing injection frequency.
Palo Alto Stock Drops as $3.35B Chronosphere Deal Overshadows Earnings Beat
Palo Alto Networks shares fall despite strong earnings as investors question expensive Chronosphere acquisition.
Nvidia Crushes Expectations with $65B Revenue Forecast Despite AI Bubble Fears
Nvidia beats expectations with $65B Q4 forecast as AI chip demand stays strong. Shares jump 4% despite concerns about sustainability of AI spending boom.
Fulcrum Gains Momentum After Agios Trial Miss
Fulcrum Therapeutics rises as Agios’ RISE UP trial falls short. Analysts say results reduce competition in sickle cell disease and strengthen Fulcrum’s position ahead of new PIONEER data.